Board Meeting-Outcome of Board Meeting
The Board in its meeting held on February 13, 2018, inter-alia, considered the following items: 1.Un-Audited Standalone and Consolidated Financial Results for the quarter ended December 31, 2017. 2.Limited Review Report on Standalone and Consolidated Financials for the quarter ended December 31, 2017 Un-Audited Financial Results For The Quarter Ended December 31, 2017
We hereby submitting un-audited standalone and consolidated financial results along with the limited review report issued by auditor for the quarter ended December 31, 2017. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vishnukant C Bhutada Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deepak Kumar Inani Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ramakant Inani Board Meeting On February 13, 2018.
We wish to inform you that a meeting of Board of Directors will be held on Tuesday, the 13th day of February, 2018 inter alia to consider the Un-audited Financial Results for the Third Quarter ended 31st December, 2017 in compliance of Regulation 33 of the SEBI (LODR) Regulations, 2015. It is further intimated that Trading Window would remain closed from 06/02/2018 to... Company News: Shilpa Medicare
Shilpa Medicare's bulk drugs units in Raichur, Karnataka, violated the same manufacturing norm of the US Food and Drug Administration for the second inspection in a row, a Cogencis US FDA completes inspection of Shilpa Medicare Raichur units
Shilpa Medicare has informed the exchanges that the US FDA has completed inspection of the company's API Unit-I and Unit-II at Raichur, Karnataka, between January 16 and 19. The FDA concluded the... Updates
This is to inform you that the US FDA has completed inspection of Company's API facilities Unit-I and Unit-II located at Raichur, Karnataka, India which was inspected between 16th January and 19th January 2018. The inspection has now been closed by the US FDA with three 483 observations. The Company is in the process of submission of corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection.... Statement Of Investor Complaints/Grievances For The Quarter Ended 30Th December, 2017
In Compliance with the requirement under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find below the statement of investor Complaints/Grievances for the quarter ended 31st December, 2017